Bitcoin sets a new all-time high above $6,000 >>> READ MORE

INSM: Insmed Stock Sinks on Study Fail

But the drug met the study's secondary goals


INSMShares of Insmed (INSM) tumbled more than 8% in Wednesday morning trading after the company conceded that a key drug had missed its primary goal in a clinical study.

INSM stock dropped on news that a Phase II study of Arikayce, considered a leading product candidate for the treatment of lung infections, failed to demonstrate significant improvement in mycobacterial density in patients suffering from nontuberculous mycobacterial lung infections, compared to those receiving a placebo, the Wall Street Journal noted.

GSK Stock Down Over Poor Cancer Drug Results
GSK Stock Down Over Poor Cancer Drug Results

However, INSM noted that the drug had shown success in producing negative cultures in patients, a secondary goal in the Phase II study. INSM indicated that it would apply for breakthrough therapy designation for the drug with the U.S. Food and Drug Administration.

Arikayce has received orphan drug status from U.S. regulators, who have also fast-tracked it.

INSM stock closed at $18.30 per share on Tuesday. Insmed stock has gained more than 140% over the past 12 months.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC